Also known as: Tecentriq (brand)
Atezolizumab is a monoclonal antibody targeting PD-L1, used in the treatment of various cancers including urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, and hepatocellular carcinoma. It works by blocking the interaction between PD-L1 and its receptors, restoring immune system anti-tumor activity. Mediocon Inc supplies pharmaceutical-grade Atezolizumab API for biopharmaceutical manufacturers.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Purity | ≥ 99% (by SEC-HPLC) |
| Endotoxin | NMT 1 EU/mg |
| Bioburden | Complies |
| Identification | Peptide Mapping Compliant |
| Storage | 2–8°C |
| Packing | As per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Atezolizumab (CAS 1380723-44-3) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Atezolizumab is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance